

PFIZER INC.

This document is provided pursuant to Regulation (EC) No 1901/2006 and Communication (2009/C 28/01)

PROPRIETARY DRUG NAME®/GENERIC DRUG NAME:

PF-06826647

PROTOCOL NO.:

C2501003

EudraCT NUMBER:

2019-003999-39

PROTOCOL TITLE:

A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With An Open Label Extension To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis

Study Centers

Data not available

Study Initiation and Final Completion Dates

Data not available. This study was cancelled prior to enrollment of any study subjects and therefore no data were collected.

Phase of Development:

Phase 2

Study Objectives:

The purpose of this study is to explore the clinical efficacy, safety, tolerability and pharmacokinetics data of PF-06826647 in the treatment of moderate to severe UC. Additionally, the study is intended to enable selection of an oral dose and dosing regimen for the future clinical development of PF-06826647 in UC.

METHODS

Data not available

RESULTS

Subject Disposition and Demography:

Data not available

Efficacy Results:

Data not available

Safety Results:

Data not available

CONCLUSION:

Data not available. This study was cancelled prior to enrollment of any study subjects and therefore no data were collected.